ADAM10 expression and promoter haplotype in Alzheimer's disease

[1]  S. Robinson,et al.  Reactive astrocytes give neurons less support: implications for Alzheimer's disease , 2012, Neurobiology of Aging.

[2]  J. Buxbaum,et al.  Evidence against a role for rare ADAM10 mutations in sporadic Alzheimer Disease , 2012, Neurobiology of Aging.

[3]  R. Postina.  Activation of α‐secretase cleavage , 2012, Journal of neurochemistry.

[4]  C. Jack,et al.  Evidence for ordering of Alzheimer disease biomarkers. , 2011, Archives of neurology.

[5]  D. Haussler,et al.  ENCODE whole-genome data in the UCSC Genome Browser: update 2012 , 2011, Nucleic Acids Res..

[6]  G. Schratt,et al.  microRNAs in neurons: manifold regulatory roles at the synapse. , 2011, Current opinion in genetics & development.

[7]  A. Kurz,et al.  Lack of evidence to support the association of polymorphisms within the alpha- and beta-secretase genes (ADAM10/BACE1) with Alzheimer's disease , 2011, Neurobiology of Aging.

[8]  G. Schellenberg,et al.  Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease , 2011, Neurobiology of Aging.

[9]  F. Fahrenholz,et al.  Expression of the Anti-amyloidogenic Secretase ADAM10 Is Suppressed by Its 5′-Untranslated Region* , 2010, The Journal of Biological Chemistry.

[10]  K. Elliott,et al.  Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate {alpha}-secretase activity. , 2009, Human molecular genetics.

[11]  F. Fahrenholz,et al.  Up‐regulation of the α‐secretase ADAM10 by retinoic acid receptors and acitretin , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  B. Bogerts,et al.  Reduced neuronal co-localisation of nardilysin and the putative α-secretases ADAM10 and ADAM17 in Alzheimer’s disease and Down syndrome brains , 2009, AGE.

[13]  R. Postina.  A closer look at alpha-secretase. , 2008, Current Alzheimer research.

[14]  Ge Li,et al.  Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. , 2006, Archives of neurology.

[15]  R. Rosenberg,et al.  Platelet amyloid precursor protein processing: A bio-marker for Alzheimer's disease , 2006, Journal of the Neurological Sciences.

[16]  F. Fahrenholz,et al.  Shedding of the amyloid precursor protein‐like protein APLP2 by disintegrin‐metalloproteinases , 2005, The FEBS journal.

[17]  J. Kaye,et al.  Safety and Acceptability of the Research Lumbar Puncture , 2005, Alzheimer disease and associated disorders.

[18]  F. Fahrenholz,et al.  Genomic structure and functional characterization of the human ADAM10 promoter , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[20]  E. Godaux,et al.  A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. , 2004, The Journal of clinical investigation.

[21]  C Caltagirone,et al.  Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease , 2004, Neurology.

[22]  R. Ravid,et al.  Levels of β-secretase BACE and α-secretase ADAM10 mRNAs in Alzheimer hippocampus , 2002 .

[23]  R. Mohs,et al.  Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. , 2002, Psychopharmacology bulletin.

[24]  M. Luca,et al.  α-Secretase ADAM10 as Well as αAPPs Is Reduced in Platelets and CSF of Alzheimer Disease Patients , 2002, Molecular medicine.

[25]  E. Kojro,et al.  Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[26]  E. Kojro,et al.  α‐Secretase Activity of the Disintegrin Metalloprotease ADAM 10: Influences of Domain Structure , 2000, Annals of the New York Academy of Sciences.

[27]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[28]  D. Selkoe,et al.  The cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease , 1998 .

[29]  R. Motter,et al.  Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease , 1997 .

[30]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[31]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[32]  G. Schellenberg,et al.  Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels. , 2008, Journal of Alzheimer's disease : JAD.

[33]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.